CD47 and Thrombocytopenia: Compared with SIRPα-Fc fusion proteins, an anti-SIRPα antibody, such as BMS-986351, provides a higher-affinity blocking capability to CD47, has single-agent activity, and has shown minimal impact on hematologic parameters, including thrombocytopenia (25, 51).